JP2019535311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535311A5 JP2019535311A5 JP2019545700A JP2019545700A JP2019535311A5 JP 2019535311 A5 JP2019535311 A5 JP 2019535311A5 JP 2019545700 A JP2019545700 A JP 2019545700A JP 2019545700 A JP2019545700 A JP 2019545700A JP 2019535311 A5 JP2019535311 A5 JP 2019535311A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- item
- scpv
- viral genome
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 58
- 108020004414 DNA Proteins 0.000 claims description 49
- 238000012986 modification Methods 0.000 claims description 42
- 230000004048 modification Effects 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 37
- 241000700647 Variola virus Species 0.000 claims description 34
- 230000003612 virological effect Effects 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 29
- 241000700618 Vaccinia virus Species 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 230000002194 synthesizing effect Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 241000700627 Monkeypox virus Species 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 238000007747 plating Methods 0.000 claims description 5
- 241000700629 Orthopoxvirus Species 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000007420 reactivation Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 241000928771 Horsepox virus Species 0.000 description 17
- 241000700564 Rabbit fibroma virus Species 0.000 description 12
- 206010016629 fibroma Diseases 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 241001476589 Squirrel fibroma virus Species 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000700626 Cowpox virus Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940124965 ACAM2000 Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241001137864 Camelpox virus Species 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 206010069582 Progressive vaccinia Diseases 0.000 description 2
- 241001455645 Rabbitpox virus Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000899864 Cherry mottle leaf virus Species 0.000 description 1
- 241000321597 Skunkpox virus Species 0.000 description 1
- 241000587120 Vaccinia virus Ankara Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013086 organic photovoltaic Methods 0.000 description 1
- 210000002151 serous membrane Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022140113A JP2022164900A (ja) | 2016-11-02 | 2022-09-02 | 合成キメラポックスウイルス |
| JP2024093677A JP2024107257A (ja) | 2016-11-02 | 2024-06-10 | 合成キメラポックスウイルス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416577P | 2016-11-02 | 2016-11-02 | |
| US62/416,577 | 2016-11-02 | ||
| US201662434794P | 2016-12-15 | 2016-12-15 | |
| US62/434,794 | 2016-12-15 | ||
| PCT/US2017/059782 WO2018085582A1 (en) | 2016-11-02 | 2017-11-02 | Synthetic chimeric poxviruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140113A Division JP2022164900A (ja) | 2016-11-02 | 2022-09-02 | 合成キメラポックスウイルス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535311A JP2019535311A (ja) | 2019-12-12 |
| JP2019535311A5 true JP2019535311A5 (enExample) | 2020-12-10 |
Family
ID=62075555
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545700A Pending JP2019535311A (ja) | 2016-11-02 | 2017-11-02 | 合成キメラポックスウイルス |
| JP2022140113A Withdrawn JP2022164900A (ja) | 2016-11-02 | 2022-09-02 | 合成キメラポックスウイルス |
| JP2024093677A Pending JP2024107257A (ja) | 2016-11-02 | 2024-06-10 | 合成キメラポックスウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140113A Withdrawn JP2022164900A (ja) | 2016-11-02 | 2022-09-02 | 合成キメラポックスウイルス |
| JP2024093677A Pending JP2024107257A (ja) | 2016-11-02 | 2024-06-10 | 合成キメラポックスウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11345896B2 (enExample) |
| EP (1) | EP3535389A4 (enExample) |
| JP (3) | JP2019535311A (enExample) |
| CN (1) | CN110431228B (enExample) |
| AU (2) | AU2017353868C1 (enExample) |
| BR (1) | BR112019008781A2 (enExample) |
| CA (1) | CA3042694A1 (enExample) |
| IL (2) | IL319942A (enExample) |
| MX (1) | MX2019005102A (enExample) |
| NZ (1) | NZ752893A (enExample) |
| SG (1) | SG11201903893PA (enExample) |
| TW (2) | TW202528334A (enExample) |
| WO (1) | WO2018085582A1 (enExample) |
| ZA (3) | ZA201902868B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017353868C1 (en) | 2016-11-02 | 2024-06-06 | Tonix Pharma Limited | Synthetic chimeric poxviruses |
| US20180228921A1 (en) * | 2017-02-13 | 2018-08-16 | Excision Biotherapeutics, Inc. | Visualizing viral reservoirs and dissemination in vivo |
| MX2020011586A (es) * | 2018-05-02 | 2020-12-07 | David Evans | Virus vaccinia quimerico sintetico. |
| WO2020153734A1 (ko) * | 2019-01-25 | 2020-07-30 | 바이로큐어 주식회사 | 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN116348135A (zh) * | 2020-02-26 | 2023-06-27 | 通尼克斯制药有限公司 | 基于重组痘病毒的抗SARS-CoV-2病毒疫苗 |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN117264909B (zh) * | 2023-10-25 | 2024-11-26 | 深圳湾实验室 | 反式互补缺陷猴痘病毒及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| CA2431349A1 (en) * | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| US20070275010A1 (en) | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| WO2006022215A1 (ja) | 2004-08-23 | 2006-03-02 | The Japan Health Sciences Foundation | SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| US20090098529A1 (en) | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
| WO2009117030A2 (en) * | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| ES2768292T3 (es) | 2013-04-10 | 2020-06-22 | Tot Shanghai R&D Center Co Ltd | Cepas de virus vaccinia mutante, usos de estas y método para producirlas |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| CN115212301A (zh) | 2015-08-11 | 2022-10-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| EP3515419A4 (en) | 2016-09-21 | 2020-06-10 | Stephen H. Thorne | High mobility group box i mutant |
| AU2017353868C1 (en) | 2016-11-02 | 2024-06-06 | Tonix Pharma Limited | Synthetic chimeric poxviruses |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| MX2020011586A (es) | 2018-05-02 | 2020-12-07 | David Evans | Virus vaccinia quimerico sintetico. |
| EP3787681A4 (en) | 2018-05-02 | 2022-01-19 | Tonix Pharma Holdings Limited | Stem cells comprising synthetic chimeric vaccinia virus and methods of using them |
-
2017
- 2017-11-02 AU AU2017353868A patent/AU2017353868C1/en active Active
- 2017-11-02 MX MX2019005102A patent/MX2019005102A/es unknown
- 2017-11-02 JP JP2019545700A patent/JP2019535311A/ja active Pending
- 2017-11-02 BR BR112019008781-8A patent/BR112019008781A2/pt active Search and Examination
- 2017-11-02 US US15/802,189 patent/US11345896B2/en active Active
- 2017-11-02 IL IL319942A patent/IL319942A/en unknown
- 2017-11-02 CA CA3042694A patent/CA3042694A1/en active Pending
- 2017-11-02 WO PCT/US2017/059782 patent/WO2018085582A1/en not_active Ceased
- 2017-11-02 TW TW113144133A patent/TW202528334A/zh unknown
- 2017-11-02 SG SG11201903893PA patent/SG11201903893PA/en unknown
- 2017-11-02 NZ NZ752893A patent/NZ752893A/en unknown
- 2017-11-02 TW TW106137976A patent/TWI887191B/zh active
- 2017-11-02 CN CN201780078546.0A patent/CN110431228B/zh active Active
- 2017-11-02 IL IL266399A patent/IL266399B2/en unknown
- 2017-11-02 EP EP17868045.0A patent/EP3535389A4/en active Pending
-
2019
- 2019-05-07 ZA ZA2019/02868A patent/ZA201902868B/en unknown
-
2022
- 2022-05-06 ZA ZA2022/04981A patent/ZA202204981B/en unknown
- 2022-05-27 US US17/827,320 patent/US12365879B2/en active Active
- 2022-09-02 JP JP2022140113A patent/JP2022164900A/ja not_active Withdrawn
-
2024
- 2024-02-15 AU AU2024200997A patent/AU2024200997A1/en not_active Abandoned
- 2024-05-02 ZA ZA2024/03393A patent/ZA202403393B/en unknown
- 2024-06-10 JP JP2024093677A patent/JP2024107257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535311A5 (enExample) | ||
| CA2786333C (en) | Vaccinia virus mutants containing the major genomic deletions of mva | |
| Bratke et al. | A survey of host range genes in poxvirus genomes | |
| JP7050044B2 (ja) | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター | |
| Cottingham et al. | Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA) | |
| Morikawa et al. | An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection | |
| JP2014207903A5 (enExample) | ||
| JP2010259446A5 (enExample) | ||
| RU2019112725A (ru) | Композиции и способы для повышения стабильности трансгенов в поксвирусах | |
| Zhang et al. | Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain | |
| CA3042694A1 (en) | Synthetic chimeric poxviruses | |
| JP2024535145A (ja) | 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用 | |
| JPWO2019213452A5 (enExample) | ||
| Zhu et al. | The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes | |
| CA2372709C (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| CN1723285A (zh) | 重组的mva及其产生方法 | |
| JPWO2021174142A5 (enExample) | ||
| Wang et al. | Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain | |
| Šroller et al. | Effect of 3-β-hydroxysteroid dehydrogenase gene deletion on virulence and immunogenicity of different vaccinia viruses and their recombinants | |
| JP7034818B2 (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| Danila | The analysis of the complete genome of Ectromelia virus strain Moscow, the causative agent of mousepox. | |
| Zhu et al. | High frequency of homologous recombination in the genome of modified vaccinia virus ankara strain (MVA) | |
| WO2016062226A1 (zh) | 复制型痘苗病毒载体艾滋病疫苗 | |
| HK40072005A (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| JPWO2019213453A5 (enExample) |